GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Current Ratio
中文

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Current Ratio : 0.56 (As of Sep. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Navidea Biopharmaceuticals's current ratio for the quarter that ended in Sep. 2023 was 0.56.

Navidea Biopharmaceuticals has a current ratio of 0.56. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Navidea Biopharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Navidea Biopharmaceuticals's Current Ratio or its related term are showing as below:

NAVB' s Current Ratio Range Over the Past 10 Years
Min: 0.11   Med: 1.29   Max: 5.42
Current: 0.56

During the past 13 years, Navidea Biopharmaceuticals's highest Current Ratio was 5.42. The lowest was 0.11. And the median was 1.29.

NAVB's Current Ratio is ranked worse than
89.39% of 1555 companies
in the Biotechnology industry
Industry Median: 3.8 vs NAVB: 0.56

Navidea Biopharmaceuticals Current Ratio Historical Data

The historical data trend for Navidea Biopharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Current Ratio Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 0.76 1.38 1.02 0.32

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.32 0.13 0.84 0.56

Competitive Comparison of Navidea Biopharmaceuticals's Current Ratio

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Current Ratio falls into.



Navidea Biopharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Navidea Biopharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=3.204/9.942
=0.32

Navidea Biopharmaceuticals's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=4.503/7.979
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Navidea Biopharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552